S1123 Underrepresentation of Minorities in the Major Biologics Trials for Crohn's Disease

Anvit D. Reddy,Nadim A. Qadir,Landen Shane Burstiner,Lauren N. Stemboroski
DOI: https://doi.org/10.14309/01.ajg.0001033860.50662.1b
2024-10-26
The American Journal of Gastroenterology
Abstract:Historically, Inflammatory Bowel Disease (IBD) was thought to predominantly affect people of Western European descent, however, this notion has changed as the incidence of IBD has been shown to grow globally. The estimated incidence of IBD per 100,000 people extrapolated from 2020 United States Census data was 812 for whites, 504 for Blacks, 403 for Asians, and 458 for Hispanics. The purpose of this study was to evaluate if patients studied in trials for biologics in Crohn's Disease (CD) reflected the changing incidence of IBD globally.
gastroenterology & hepatology
What problem does this paper attempt to address?